{"name":"Shanghai JMT-Bio Inc.","slug":"shanghai-jmt-bio-inc","ticker":"","exchange":"","domain":"shanghaijmtbio.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Anti-RANKL Monoclonal Antibody","genericName":"Anti-RANKL Monoclonal Antibody","slug":"anti-rankl-monoclonal-antibody","indication":"Osteoporosis","status":"phase_1"},{"name":"Cyclosporin Capsules","genericName":"Cyclosporin Capsules","slug":"cyclosporin-capsules","indication":"Prevention of organ rejection in transplant patients","status":"phase_2"},{"name":"Placrbo","genericName":"Placrbo","slug":"placrbo","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"HB1801","genericName":"HB1801","slug":"hb1801","indication":"Advanced solid tumors (Phase 3 development)","status":"phase_3"},{"name":"KN026","genericName":"KN026","slug":"kn026","indication":"HER2-positive gastric cancer","status":"phase_3"},{"name":"Osimertinib tablet","genericName":"Osimertinib tablet","slug":"osimertinib-tablet","indication":"Metastatic non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations (first-line)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"SG001","genericName":"SG001","slug":"sg001","indication":"Type 2 diabetes","status":"phase_3"},{"name":"JMT103","genericName":"JMT103","slug":"jmt103","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"JMT101 injection","genericName":"JMT101 injection","slug":"jmt101-injection","indication":"Treatment of moderate to severe rheumatoid arthritis","status":"phase_3"}]}],"pipeline":[{"name":"SG001","genericName":"SG001","slug":"sg001","phase":"phase_3","mechanism":"SG001 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Anti-RANKL Monoclonal Antibody","genericName":"Anti-RANKL Monoclonal Antibody","slug":"anti-rankl-monoclonal-antibody","phase":"phase_1","mechanism":"Inhibits RANKL","indications":["Osteoporosis"],"catalyst":""},{"name":"Cyclosporin Capsules","genericName":"Cyclosporin Capsules","slug":"cyclosporin-capsules","phase":"phase_2","mechanism":"Cyclosporin Capsules inhibit calcineurin, preventing T-cell activation and proliferation.","indications":["Prevention of organ rejection in transplant patients"],"catalyst":""},{"name":"HB1801","genericName":"HB1801","slug":"hb1801","phase":"phase_3","mechanism":"HB1801 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.","indications":["Advanced solid tumors (Phase 3 development)"],"catalyst":""},{"name":"JMT101 injection","genericName":"JMT101 injection","slug":"jmt101-injection","phase":"phase_3","mechanism":"JMT101 injection is a monoclonal antibody targeting a specific protein to modulate the immune system.","indications":["Treatment of moderate to severe rheumatoid arthritis"],"catalyst":""},{"name":"JMT103","genericName":"JMT103","slug":"jmt103","phase":"phase_3","mechanism":"JMT103 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"KN026","genericName":"KN026","slug":"kn026","phase":"phase_3","mechanism":"KN026 is a bispecific antibody that simultaneously binds to HER2 and HER3 receptors to block their signaling pathways in cancer cells.","indications":["HER2-positive gastric cancer","HER2-positive breast cancer"],"catalyst":""},{"name":"Osimertinib tablet","genericName":"Osimertinib tablet","slug":"osimertinib-tablet","phase":"phase_3","mechanism":"Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations, blocking downstream signaling in cancer cells.","indications":["Metastatic non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations (first-line)","Metastatic non-small cell lung cancer with EGFR T790M mutation (second-line, after progression on first/second-generation EGFR inhibitors)"],"catalyst":""},{"name":"Placrbo","genericName":"Placrbo","slug":"placrbo","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQVnBsSnlmWGRreUxQMkZ4U1BLeFJlYk5fVlRReXRQTjhYUlhIZjNvX05mVlgtSzBLMC0xaEpiblg0cEwwOWpfd2NUVngxMEVMczVyeHc0X2c3OGZoaUNCODVXSUV2aDBpdmpQYnlwMTlKei02Si1EV1EyelRxWmNXbGI0NDMwdnItSWx4U1RGT2RQcVpxYlc5b0VJX0tHblNrSU1qdjg0bkdfTVFsZHVya01UdU4tRTdEclMzT0ZzaWdDbEFw?oc=5","date":"2026-03-31","type":"trial","source":"TipRanks","summary":"CSPC’s Anbenitamab Combo Hits Phase III Goal in HER2-Positive Breast Cancer - TipRanks","headline":"CSPC’s Anbenitamab Combo Hits Phase III Goal in HER2-Positive Breast Cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxNc1lsTmVGYmFzSGkzRXlVX2RMeDI2UlQ0VVJBVkhYMkQ1VlpaMFNCX3gtdzBwZEU5UWtUbWNPWmxhMm5jQ3AyMWtMMXhkVW9RSlM2bTNzVy1SdUt6Vmp0Wjk3T0tvUGZHQktEc1B0aTBBbUNfelU4XzFoOHZWVEdrVFpNYklZbFZNQWFDUlFhbVFaaDdYVE03VlNvdk9VczhYY2Q2Ul9KX0F3c3RKQk1QZVQxa3BuOEJOMnQ2Q1lwc3hLYkc5UEtSWm1wTVNHMVpaQ2Y1SmQ3dGljYS1aWjNIWVotRUI1T1lTLUZMb3ROenV5T2ZPOVl5cnVBV19CbTNabnRhOGQzSXhhY1pDWnBXOGFabw?oc=5","date":"2026-03-21","type":"trial","source":"Barchart.com","summary":"HER2 Positive Gastric Cancer Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com","headline":"HER2 Positive Gastric Cancer Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Ma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNR29wLTRZb0FBMGRqRDV0d25jRWJDb3NlaFg5Qkc0NkRRUnFsZG1CNzdJaEZzV1JjLWxtYnVrVElHX0NfX1JyVHlFRXlHWUdWdHdLLW9qbFBIYTdEckU0SXB0b0ZYRUNZX1JWT0kzczBZN3VPakxnX1h3WlpBcGJkTDdVRlMyeGhiRDBYblllVHJaZw?oc=5","date":"2026-03-21","type":"trial","source":"openPR.com","summary":"HER2 Positive Gastric Cancer Clinical Trial Pipeline - openPR.com","headline":"HER2 Positive Gastric Cancer Clinical Trial Pipeline","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPN2RRTE1VSWxYZnp2eW8tMDk4Z1pMdDRuazY5Z2VBRFVaQlJmVF92UVU1aEFIUnlxdmI2dHVlRFhnN0I5Z1U3SmFubjVKZFFXbWJ1eUE0MU1UdElibFBsc2RoaVc3Wi1EbnlEczdXTDQza2hySGZMajhzd295YjJnNg?oc=5","date":"2025-10-09","type":"pipeline","source":"DCAT Value Chain Insights","summary":"Bispecific ADCs: The Next Targeted Therapy? - DCAT Value Chain Insights","headline":"Bispecific ADCs: The Next Targeted Therapy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNcGpNeFNQY0hJZlUxSzNkTXJxdVhhdzgycWRKNk5jZHFTUmJ2cjNXU0FjV2p0OFhiY0xFTUhVV1otUUJZanJsNzFVamFKN19mZkNVLThWNmxfZTVXaVNpOEtaX3RJamk0N1RrbGk4ajAxMEpMQUtjSzJISjNSekZXbXhYYXJuc1BEY2NEckNIaW9oNFBlS3RMUmxsNzNFeFdKUGZ1bTh2bWluZEJBM0hHRG5WWWItWWtFZ0Fvd2xFeE03X09VRzQ0eg?oc=5","date":"2025-09-01","type":"regulatory","source":"European Pharmaceutical Review","summary":"Chinese ADC dominance expected to drive the first bispecific approval - European Pharmaceutical Review","headline":"Chinese ADC dominance expected to drive the first bispecific approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxOX0tWV1VaVnlYcXVwVnNxa1o0cDZ6eHQwMDR6VUUzTE9UdlFPVVhKMkFxRTNDUTA4bWo5UnFid0hLaHh2bVpDaGJvbHFTakpsSTF4TUFTSEkwOF9EV215M0d6REs3clN6UHQwZ0Q2bWtxM3Y0VkhSRUxtYVoxbEFweUg3WnYweGNmenkyM21jeGNhcFpQcm1BOWxnNF9LeTNyaFNtZDRFWWFKRUNXbk1hMnFJYkZuWHl5Zk1fSERRcXBoWnpfVFBDR2M1dVNrXy1IMkdzcGFtdzdvWGdWSnY2M0tHWWo5WFVwVG9PZjRwWldZbWt6aFFHUVlVek0yWHBCZUV2UHpmcEI5N0syUXRyT1A2ckpOdmc?oc=5","date":"2025-08-07","type":"trial","source":"GlobeNewswire","summary":"Cancer Cachexia Clinical Trial Pipeline Shows Potential - GlobeNewswire","headline":"Cancer Cachexia Clinical Trial Pipeline Shows Potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPVGhudTlQdmVrczBXOEY2Z3pDTmNKSWhVNXZvM3Jka1Y3VkhKMFdZYzIyaE9fb240SklNeVhWWWppRFhERWNOZ0FSQ2d6eU9zc2JaWmdqMWdkc1Nub1pXOHk5dkpGNk1kcXJkbjJBVzZGS041dkg1ODJsYUxCOGE2bkMzMzF2RUgyTlFsZXQtOFU2VFdPenk4dzBYQ0FoVl9wWnhMT1RZSm8zZw?oc=5","date":"2025-06-10","type":"deal","source":"BioWorld News","summary":"Ligachem inks two mystery ADC deals with CSPC subsidiary Novarock - BioWorld News","headline":"Ligachem inks two mystery ADC deals with CSPC subsidiary Novarock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFB2ZGJvWmFFLVVfQk1IZ2txa3l3TnJZc0cxOFhhVGwzQWNTNWR2cGFwX0wwNmhNenA1cjFXV012eWtWbDBBUVFpdEdwNVMyQ3ZheUYza1dGUHFfdzlId1pER3dHaHAxY3ZEdktTcHBB?oc=5","date":"2024-10-30","type":"deal","source":"Law.asia","summary":"CSPC signs an exclusive license agreement with Jiangsu Alphamab for the development and commercialization of JSKN003 in mainland China - Law.asia","headline":"CSPC signs an exclusive license agreement with Jiangsu Alphamab for the development and commercialization of JSKN003 in ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gJBVV95cUxPRmEzaWZ4OEpmb2dTTEpYbXRYdFlmbkFFY0JtVW9oVDFteEo4dWRxN2NYMWFVNmwzdG5pSkFvek9xa21hRXRsaDhEV29fblpnLU5HWUtOYzVxVGFyOFBvUHhCUjB3REFjcTVmVjVEV2g0LXRnVGFXMFllUGMtQW1JbUJWNEtRdjk3em52eE1fY0Z6UDhlMG90WFNwWnFzNk5WME9XQktuaDVhX0didF8yM1JpTzRIMkpWSFl5c2xqSHB5WkVZWHdkb2lrT295YmI4LVV5YkJPOGNmTjEwYUFId2dWSXA5NXhvUlI4T19zTlM3VkNSR0VnM0NSMEViSE1BMU5STnliWnRYeS1GQW1lSmlua3NDVWFVaURWQV8xem1ZRjhGbGh2Wk1CaUJWclM4bXVpa1NQUkxoVVpuZXA3ZFZrLTgxUTRSVVY1TWFnUzUwSHFvd2UzbG8wVVNHVXhaamxMdDNELTktSmVtcWF6S1N3?oc=5","date":"2023-06-22","type":"pipeline","source":"PR Newswire","summary":"Osteoporosis Market to Accelerate Substantially, Assesses DelveInsight | Key Companies to Look Out For - Teva, Novartis, Amgen, USB, Jiangsu HengRui Medicine, Shanghai JMT-Bio, Eli Lilly and Company, ","headline":"Osteoporosis Market to Accelerate Substantially, Assesses DelveInsight | Key Companies to Look Out For - Teva, Novartis,","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_3":6,"phase_1":2,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}